CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 455 enrolled
Drug / intervention
AFX EVAR AAA Graft System +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02407457
NCT02407457N/ACompleted
CompareCT.gov

Multicenter, Post-Market Study to Assess Outcomes of Patients Treated With the AFX System Compared to Other EVAR Devices for Endovascular Abdominal Aortic Aneurysm Repair: LEOPARD

Endologix·interventional·Posted Apr 3, 2015·Updated Oct 1, 2024

In Brief

A clinical study evaluating AFX EVAR AAA Graft System and FDA Approved EVAR AAA Graft Systems for Abdominal Aortic Aneurysm. Completed, enrolled 455 participants across 56 sites.

Detailed Summary

The objective of this post-market trial is to evaluate Endologix AFX endovascular AAA system with anatomical fixation against other approved Endovascular systems with proximal fixation. Multiple U.S clinical centers will be involved in the trial to include a broad range of experience. Imaging data will be evaluated by an independent core lab.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAbdominal Aortic Aneurysm
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 3, 2015
Enrollment StartMar 1, 2015
Primary CompletionOct 1, 2018
Study CompletionOct 1, 2022
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 11.2 years ago

Interventions

AFX EVAR AAA Graft Systemdevice

Endvovascular Abdominal Aneurysm Repair (EVAR) using commerically available, FDA approved endovascular graft systems implanted via femoral access.

FDA Approved EVAR AAA Graft Systemsdevice